Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Wall Street Analyst Weigh In

YMAB has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $63.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, April 29th. BMO Capital Markets initiated coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, June 23rd. They set an "outperform" rating and a $27.00 price objective on the stock. Finally, Wedbush cut their price objective on shares of Y-mAbs Therapeutics from $28.00 to $21.00 and set an "outperform" rating on the stock in a report on Tuesday, May 10th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.83.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB Stock opened at $17.29 on Thursday. The company has a market capitalization of $755.92 million, a price-to-earnings ratio of -5.60 and a beta of 1.15. Y-mAbs Therapeutics has a one year low of $6.50 and a one year high of $34.60. The company's 50-day moving average is $16.11 and its 200 day moving average is $12.34.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.26). Y-mAbs Therapeutics had a negative net margin of 338.68% and a negative return on equity of 79.40%. The firm had revenue of $10.80 million for the quarter, compared to analysts' expectations of $11.22 million. During the same quarter in the previous year, the company earned ($0.53) EPS. The company's quarterly revenue was down 1.4% compared to the same quarter last year. As a group, research analysts predict that Y-mAbs Therapeutics will post -1.94 earnings per share for the current fiscal year.